Ardelyx Inc

NASDAQ:ARDX   3:59:54 PM EDT
6.32
+0.01 (+0.16%)
Regulatory, Other Pre-Announcement

Ardelyx Inc Reports Data From Phase I Clinical Trial Of RDX013

Published: 11/12/2020 22:37 GMT
Ardelyx Inc (ARDX) - Ardelyx Inc - Updated Progress With Respect to Its Small Molecule Potassium Secretagogue Program, Rdx013, for Potential Treatment of Hyperkalemia.
Ardelyx Inc - Data From Phase 1 Clinical Study Showed Rdx013 Was Generally Safe and Well-tolerated.
Ardelyx Inc - Currently Expects to Initiate Phase 2 Study for Rdx013 in Next Several Months.